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Abstract: Glioblastoma multiform is one of the most rapidly progressing cerebral tumors 
and the most aggressive one in our neurosurgical experience. We present the case of a 45 
year old patient with very aggressive type of tumor who had come to our service for the 
following: intense headache, confusion, right hemiparesis installed approximately one 
month before. IRM scan shows up the presence of a large tumoral mass without a precise 
border in the left temporal-parietal region which had extended all the way down to the 
thalamus. The planned intervention used 5-aminolevulinic acid (5-ALA) for the precise 
removal of the tumor mass, suboptimal because of the risk of lesioning the motor tracts – 
indicated by the intraoperative electrophysiological monitoring. After surgery the outcome 
was good with the partial regression of the motor deficit, but only after 3 weeks due to the 
unexpected tumor growth the neurological status started to decay and even worsened. The 
patient underwent surgery again with the partial remission of the symptoms although 
following imagistic controls showed up fast tumor growth once more. He was 
recommended to oncology service for the beginning of radiotherapy. We consider the 
evolution and invasion of this tumor in only a 3 weeks period being impressive.      
Key words: glioblastoma multiform, 5-aminolevulinic acid (5-ALA), recurrent disease, 
re-operation 
 
Background 
Glioblastoma multiforme is one of the 
most rapidly growing cerebral tumors and the 
most aggressive one in our neurosurgical 
experience. It is a glial cell tumor, a glioma and 
it originates in the support cells of the brain – 
glial cells or in their precursors. Unfortunately, 
it is the most common primary brain tumor 
occurring during adulthood (20%), and the 
most frequent glial cell tumor – 51% of all 
gliomas (1). The confirmation of a 
glioblastoma by histological diagnosis is a 
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devastating condition, and it certainly 
represents a turn point in our patients’ 
journey. American Brain Association indicates 
an average survival rate of 14 months, less than 
10% of all the patients managing to survive 
more than 5 years with all the current available 
therapeutic methods (2). We can tell without a 
doubt, it’s quite aggressive, for example, one of 
the worst and well known tumors for their 
high malignancy rate –the small cell lung 
carcinoma – has a median survival rate of 20 
months and 20% of the patients are still alive 
after 5 years (3). The term of multiforme 
suggests that GBM are complex tumors with 
various aspects in grossly, microscopy and in 
various types of imaging methods, with 
complex clinical manifestations, complex 
genetic patterns, and, of course, various 
growing behavior.  
The current standard treatment include a 
radical surgical resection followed by radio- 
and chemotherapy. The important thing for us 
as surgeons and what matters above all else is 
what we can surgically do to improve the 
patient’s survival rate and his quality of life. 
There are many studies that emphasized the 
importance of the gross total resection (GTR) 
in the treatment of these aggressive tumors. 
GTR may be considered as a valuable 
independent prognostic factor for our patients 
survival, and a GTR of 98% or more of the 
tumor volume, as it can be appreciated on MRI 
enhanced images, is considered mandatory for 
a better evolution and prognosis (4, 5, 6). 
Other important prognostic factors are patient 
age and performance status (7). Despite 
improved surgical techniques, therapies and 
radiotherapies, prognosis for this type of 
pathology remains very poor: most patients 
die within 12–18 months from diagnosis (8). 
In order to improve the extent of the 
resection we use 5-aminolevulinic acid (5-
ALA)-induced fluorescence to guide our 
procedure and, of course, the intraoperative 
neuromonitoring for the safety of our 
resection. 
Case presentation   
We present a 45 year-old man which was 
admitted in December 2016 to the Emergency 
Clinical Hospital “Prof. Dr. N Oblu’’, Iasi; for 
about a month he had been suffering  from 
intense headache, confusion, and loss of 
strength of the right arm and leg. A CT and 
MRI scan showed the presence of a tumor in 
the temporal-parietal region of the left 
hemisphere with thalamic extension (Figure 1) 
We performed a tumor excision using 5-
aminolevulinic acid (5-ALA), and 
electrophysiological monitoring of the motor 
cortex and tracts - with favorable outcome 
after surgery and progressive remission of the 
previously installed motor deficit. He attended 
neuromotor rehabilitation treatment. The 
resection was less than desired -subtotal - 
because of the MEP-s which indicates the 
vicinity of the motor tracts. 
After 3 weeks from the procedure, before 
attending any oncological complementary 
treatment, he came to the Emergency 
Department of our hospital   with motor 
aphasia, right hemiplegia and sleepiness which 
had occurred 3 days before. CT scan with 
contrast shows up unexpected large tumor 
growth and invasion and hydrocephalus due to 
the Monro and Sylvius aqueduct compression 
(Figure 3). The patient was reoperated on the 
next day. Postoperative evolution was favorable 
with partial remission of the motor deficit and 
aphasia, and the patient was addressed to the 
oncological department in 2 weeks for 
radiotherapy and temozolomide treatment.  
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Figure 1 - a) CT scan- axial section   b) MRI scan -
axial and coronal sections- image preoperative – 
glioblastoma involving the left thalamus 
 
 
Figure 2 - Enhanced CT scan first day after surgery – 
small tumoral remnant in thalamus [1] 
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Figure 3 - CT with IVC showing the large, 
precocious, invasive tumor evolution 
 
 
 
 
Figure 4 - MRI post-op [2] 
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Figure 5 - Ct post radiotherapy simulation 
Discussion 
The aggressively character of glioblastomas 
was described for the first time since 1926, 
when Bailey and Cushing described some 
unusual rapidly growing forms of astrocytic 
tumors (9). There are many studies now which 
emphasize the importance of molecular and 
genetic abnormalities in the behavior of a 
particular type of glioblastoma. Even some 
GBM may be histologically identical, they are 
molecularly distinct, and this individuality 
influence their evolution, but, of course, may 
require a specific tailored treatment (10). We 
believe that our patient had one of this very 
aggressive type of tumor, the evolution and 
invasion in only a 3 weeks period being 
impressive.      
The use of substances like 5-
Aminolevulinic acid hydrochloride (11), 
which mark and thus make tumoral tissue 
easier to identify during an operation, have 
improved surgery for cerebral gliomas; in fact 
they allow for a more thorough excision (12), 
but increased the risk for postoperative 
complications like neurological deficit, so the 
using of intraoperative neuromonitoring is 
mandatory in order to decrease this potential 
risk. We experienced that in our case, finally 
we were not able to resect all the amount of 
tumor revealed by 5-ALA intraoperative 
visualization because of the electric imperative 
risk signs for motor deficit. In fact the initial 
motor deficit increased after the surgery but 
with good recovery, that may indicate the 
value of the electrophysiology in stopping us in 
time, but also it indicates that the use of the 5-
ALA may be risky in the absence of experience 
and carefully monitoring. 
Repeat surgery may play a role in 
debulking the tumor, providing symptom 
relief, and differentiating tumor recurrence 
from pseudo-progression or radiation necrosis 
(grade of recommendation: B). However, 
before surgical intervention, it is essential to 
clearly define treatment goals and the effect on 
prognosis and quality of life for the patient 
(13). Studies have shown that GBM recurrence 
most often occurs in the form of a local 
continuous growth within 2 to 3 cm from the 
border of the original lesion. Choucair, et al. 
reported that more than 90% of patients with 
glioma showed recurrence at the original 
tumor location and that multiple lesions 
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developed in 5% after treatment (14). 
We emphasize the importance of 
performing oncology treatment. An important 
part of a high-grade glioma treatment is 
radiotherapy. In typical situations, patients 
begin radiation treatments within 2 to 4 weeks 
after tumor resection (15). Our patient has not 
started radiotherapy after the first 
intervention, which probably caused tumor 
growth. 
Conclusion 
Unfortunately, despite all intensive studies, 
surgical and oncological advances, GBM 
remains the cerebral tumors with the worst 
prognosis. Between these bad tumors, there 
are some cases with even quicker evolution 
and extensive invasion. What make them 
behave like is a subject for many molecular and 
genetic studies. The use of 5-ALA and 
intraoperative neuromonitoring may help the 
extension of a safety resection. The precocity 
of radio-chemotherapy treatment is 
mandatory, especially in aggressive cases. 
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